UY33497A - Derivados de espiro-piperidina como moduladores s1p - Google Patents

Derivados de espiro-piperidina como moduladores s1p

Info

Publication number
UY33497A
UY33497A UY0001033497A UY33497A UY33497A UY 33497 A UY33497 A UY 33497A UY 0001033497 A UY0001033497 A UY 0001033497A UY 33497 A UY33497 A UY 33497A UY 33497 A UY33497 A UY 33497A
Authority
UY
Uruguay
Prior art keywords
derivatives
espiro
modulators
piperidine
receptors
Prior art date
Application number
UY0001033497A
Other languages
English (en)
Inventor
Stoit Axel
Bakker Wouter L Iwema
Hein K A C Coolen
Dongen Maria J P Van
Nicolas J-L D Leflemme
Original Assignee
Abbot Healthcare Products B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbot Healthcare Products B V filed Critical Abbot Healthcare Products B V
Publication of UY33497A publication Critical patent/UY33497A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con derivados de espiro-amina cíclica de la fórmula (I). Los compuestos de la invención tienen afinidad a los receptores S1P y se pueden utilizar en el tratamiento, alivio o prevención de enfermedades o afecciones en las que involucran (a) los receptores S1P.
UY0001033497A 2010-07-09 2011-07-08 Derivados de espiro-piperidina como moduladores s1p UY33497A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10169104 2010-07-09
EP11154961 2011-02-18

Publications (1)

Publication Number Publication Date
UY33497A true UY33497A (es) 2012-01-31

Family

ID=44315247

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033497A UY33497A (es) 2010-07-09 2011-07-08 Derivados de espiro-piperidina como moduladores s1p

Country Status (23)

Country Link
US (4) US10179791B2 (es)
EP (2) EP3144312A1 (es)
JP (1) JP5922115B2 (es)
KR (1) KR101889695B1 (es)
CN (1) CN103097364B (es)
AR (1) AR082135A1 (es)
AU (1) AU2011275760B2 (es)
BR (1) BR112013000629B1 (es)
CA (1) CA2804143C (es)
DK (1) DK2590955T3 (es)
ES (1) ES2606137T3 (es)
HK (1) HK1184153A1 (es)
IL (1) IL224049B (es)
MX (1) MX347423B (es)
NZ (1) NZ605486A (es)
PL (1) PL2590955T3 (es)
PT (1) PT2590955T (es)
RU (2) RU2602800C2 (es)
SG (1) SG186926A1 (es)
TW (2) TW201643169A (es)
UY (1) UY33497A (es)
WO (1) WO2012004378A1 (es)
ZA (1) ZA201300153B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48301E1 (en) 2010-07-09 2020-11-10 Abbvie B.V. Fused heterocyclic derivatives as S1P modulators
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
CN102250035A (zh) * 2011-06-10 2011-11-23 北京富卡生物技术有限公司 二芳基取代-1，3，4-噁二唑化合物的合成方法和其药物用途
US8642585B2 (en) * 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
US8809376B2 (en) 2012-04-30 2014-08-19 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
JP6283862B2 (ja) 2012-12-07 2018-02-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規インダニルオキシジヒドロベンゾフラニル酢酸
KR101598612B1 (ko) * 2013-08-29 2016-02-26 재단법인 아산사회복지재단 Dpp-4 억제제를 포함하는 혈관 또는 심장판막 석회화의 예방 또는 치료용 조성물
CN107253903B (zh) * 2016-06-20 2020-11-24 北京海步医药科技股份有限公司 制备一种能够结合s1p受体化合物及其中间体的方法
WO2018083171A1 (en) 2016-11-02 2018-05-11 AbbVie Deutschland GmbH & Co. KG Spiro-compounds as s1p modulators
JP7050791B2 (ja) 2017-01-26 2022-04-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
CN110312714B (zh) 2017-01-26 2022-12-09 勃林格殷格翰国际有限公司 苄基氧基吡嗪基环丙烷甲酸、其药物组合物和用途
EP3573952B1 (en) 2017-01-26 2021-07-14 Boehringer Ingelheim International GmbH Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceuticalcompositions and uses thereof
EP3573959B1 (en) 2017-01-26 2021-07-28 Boehringer Ingelheim International GmbH Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
EP3580222B1 (en) 2017-02-08 2021-04-07 Boehringer Ingelheim International GmbH Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
US10981900B2 (en) * 2017-02-28 2021-04-20 Medshine Discovery Inc. Spiro compound and use thereof
CN110092774B (zh) * 2018-01-29 2022-04-08 中国科学院上海药物研究所 芳香丙酸类衍生物、及其制备方法和用途
CA3103711A1 (en) * 2018-07-12 2020-01-16 UCB Biopharma SRL Spirocyclic indane analogues as il-17 modulators
JP2022553802A (ja) 2019-10-31 2022-12-26 エスケープ・バイオ・インコーポレイテッド Ｓ１ｐ受容体モジュレーターの固体形態
US20220169620A1 (en) * 2020-12-01 2022-06-02 AbbVie Deutschland GmbH & Co. KG Spiro-cyclic amine derivatives as s1p modulators
WO2024179529A1 (zh) * 2023-02-28 2024-09-06 上海海雁医药科技有限公司 取代的三环衍生物及其药物组合物和用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962259A (en) 1973-12-12 1976-06-08 American Hoechst Corporation 1,3-Dihydrospiro[isobenzofuran]s and derivatives thereof
US3980787A (en) * 1975-08-25 1976-09-14 American Hoechst Corporation 3-Phenylspiro[isobenzofuran-1,4'-piperidine]sulfenamides and derivatives
SU1069387A1 (ru) 1982-07-01 1985-11-30 Институт физико-органической химии и углехимии АН УССР Дигидрохлорид 5-/ @ -( @ -анизил)- @ -оксиэтил/ 2-(3,4-диметоксифенил)-1-метил-4,5,6,7-тетрагидроимидазо(4,5- @ )пиридина,обладающий спазмолитическим действием
GB2228432A (en) 1989-01-13 1990-08-29 Grayston Central Services Multi-role machine for heating and coating pipe welds.
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
JPH03206042A (ja) 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
JP2681589B2 (ja) 1992-12-28 1997-11-26 日揮株式会社 配管溶接継手の熱処理方法
JPH072848A (ja) 1993-04-23 1995-01-06 Sankyo Co Ltd モルホリンおよびチオモルホリン誘導体
GB9522845D0 (en) * 1995-11-08 1996-01-10 Smithkline Beecham Plc Novel compounds
JP3822680B2 (ja) 1996-08-30 2006-09-20 新日本製鐵株式会社 誘導加熱された接合部の冷却方法および冷却装置
TWI243173B (en) * 1999-11-17 2005-11-11 Akzo Nobel Nv Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
WO2001083463A1 (fr) 2000-04-21 2001-11-08 Shionogi & Co., Ltd. Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaires
FR2822727A1 (fr) 2001-04-03 2002-10-04 Gesal Ind Procede d'application d'un revetement resistant aux hautes temperatures, dispositif pour la mise en oeuvre de ce procede et objet pourvu dudit revetement
JP3649223B2 (ja) 2003-01-08 2005-05-18 株式会社日立製作所 配管系の熱処理方法および熱処理装置
CA2526209A1 (en) 2003-06-12 2004-12-23 Btg International Limited Cyclic hydroxylamine as psychoactive compounds
JP4861177B2 (ja) 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
US7550485B2 (en) 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
EP1716148A2 (en) 2003-12-23 2006-11-02 Arena Pharmaceuticals, Inc. Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2005092858A2 (en) * 2004-03-29 2005-10-06 Pfizer Japan Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
BRPI0510453A (pt) 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
GB0409744D0 (en) 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
WO2006047195A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
JP4491334B2 (ja) 2004-12-01 2010-06-30 日立Ｇｅニュークリア・エナジー株式会社 配管の熱処理方法および装置
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
JP4599250B2 (ja) 2005-08-10 2010-12-15 株式会社東芝 高周波誘導加熱時外面温度制御方法および当該制御装置
JP2007063642A (ja) 2005-09-01 2007-03-15 Hitachi Ltd 残留応力改善方法と高周波誘導加熱用コイル
NZ568292A (en) * 2005-11-10 2011-08-26 Msd Kk Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
WO2007057775A1 (en) 2005-11-21 2007-05-24 Pfizer Limited Spiropiperidine derivatives
AU2006330866A1 (en) * 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CA2637308C (en) 2006-01-27 2014-02-25 F. Hoffmann-La Roche Ag Use of 4-imidazole derivatives for cns disorders
KR20080080410A (ko) 2006-01-27 2008-09-03 에프. 호프만-라 로슈 아게 이미다졸린 유도체의 치환된 2-이미다졸의 용도
ES2462240T3 (es) 2006-02-28 2014-05-22 Dart Neuroscience (Cayman) Ltd Piperazinas terapéuticas como inhibidores de PDE4
WO2007109334A2 (en) 2006-03-21 2007-09-27 Epix Delaware, Inc. Sip receptor modulating compounds and use thereof
GB0608452D0 (en) * 2006-04-27 2006-06-07 Glaxo Group Ltd Novel compounds
EP2049548A1 (en) 2006-07-27 2009-04-22 UCB Pharma, S.A. Fused oxazoles & thiazoles as histamine h3- receptor ligands
AR062677A1 (es) 2006-09-08 2008-11-26 Novartis Ag Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
CA2672727A1 (en) * 2006-12-21 2008-07-03 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
WO2008096746A1 (ja) 2007-02-06 2008-08-14 Takeda Pharmaceutical Company Limited スピロ化合物およびその用途
EP2148863A1 (en) 2007-04-23 2010-02-03 Novartis Ag Phthalazine and isoquinoline derivatives with slp receptor modulating activities
WO2009084501A1 (ja) 2007-12-27 2009-07-09 Asahi Kasei Pharma Corporation スルタム誘導体
EP2238144A1 (en) 2008-01-24 2010-10-13 UCB Pharma, S.A. Compounds comprising a cyclobutoxy group
CN101932585B (zh) 2008-01-30 2013-07-10 赛福伦公司 作为组胺-3(h3)受体配体的取代的螺环哌啶衍生物
JP5524083B2 (ja) * 2008-01-30 2014-06-18 セファロン、インク． ヒスタミン−３（ｈ３）受容体リガンドとしての置換スピロ環状ピペリジン誘導体
US20090321144A1 (en) 2008-06-30 2009-12-31 Wyble Kevin J Protecting an element from excessive surface wear by localized hardening
AR077969A1 (es) 2009-08-31 2011-10-05 Abbott Healthcare Products Bv Derivados de (tio)morfolina comomoduladores de s1p
PT2531177T (pt) 2010-02-04 2016-08-17 Esteve Labor Dr Polimorfos e solvatos de cloridrato de 4-[-2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina
CN101812058B (zh) 2010-04-13 2012-03-21 湖南大学 吲哚美辛2-芳基吗啉乙酯及其制备方法与应用
TWI522361B (zh) 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
TW201206893A (en) 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
US10179971B2 (en) 2014-03-21 2019-01-15 Iogen Energy Corporation Method for processing a cellulosic feedstock at high consistency
JP2022553802A (ja) 2019-10-31 2022-12-26 エスケープ・バイオ・インコーポレイテッド Ｓ１ｐ受容体モジュレーターの固体形態
US20210139503A1 (en) 2019-10-31 2021-05-13 ESCAPE Bio, Inc. Processes for preparing an s1p-receptor modulator

Also Published As

Publication number Publication date
IL224049B (en) 2018-11-29
CA2804143C (en) 2020-03-10
US20190218227A1 (en) 2019-07-18
MX347423B (es) 2017-04-26
ZA201300153B (en) 2018-12-19
EP2590955B9 (en) 2017-02-22
US20210130364A1 (en) 2021-05-06
KR101889695B1 (ko) 2018-08-21
CN103097364A (zh) 2013-05-08
RU2016140266A (ru) 2018-12-13
WO2012004378A1 (en) 2012-01-12
PL2590955T3 (pl) 2017-03-31
JP5922115B2 (ja) 2016-05-24
AR082135A1 (es) 2012-11-14
BR112013000629B1 (pt) 2020-12-15
AU2011275760B2 (en) 2015-08-13
BR112013000629A2 (pt) 2016-05-24
EP2590955B1 (en) 2016-10-12
AU2011275760A1 (en) 2013-01-31
TWI543984B (zh) 2016-08-01
US20130196998A1 (en) 2013-08-01
KR20130050353A (ko) 2013-05-15
RU2602800C2 (ru) 2016-11-20
US20160340363A1 (en) 2016-11-24
US11427598B2 (en) 2022-08-30
RU2013105490A (ru) 2014-08-20
CA2804143A1 (en) 2012-01-12
US9951084B2 (en) 2018-04-24
MX2013000362A (es) 2013-07-17
EP2590955A1 (en) 2013-05-15
DK2590955T3 (en) 2016-12-05
SG186926A1 (en) 2013-02-28
HK1184153A1 (zh) 2014-01-17
JP2013535412A (ja) 2013-09-12
US10807991B2 (en) 2020-10-20
TW201643169A (zh) 2016-12-16
RU2016140266A3 (es) 2018-12-13
PT2590955T (pt) 2016-11-17
TW201211051A (en) 2012-03-16
NZ605486A (en) 2014-08-29
ES2606137T3 (es) 2017-03-22
CN103097364B (zh) 2015-11-25
EP3144312A1 (en) 2017-03-22
US10179791B2 (en) 2019-01-15

Similar Documents

Publication Publication Date Title
UY33497A (es) Derivados de espiro-piperidina como moduladores s1p
ECSP22091792A (es) Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos
NI201500077A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
ECSP13013074A (es) Nuevos derivados de piridina
CR20150250A (es) Nuevos derivados de piridina
CR20170500A (es) Compuestos heterocíclicos como inhibidores de lsd1
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
CR20150204A (es) Nuevos derivados de piridina
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
GT201400187A (es) Derivados macrocíclicos para el tratamiento de enfermedades
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
BR112016000909A8 (pt) derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
CU20170037A7 (es) Compuestos derivados de n-alquilaril-5-oxiaril-octahidro ciclopenta[c)pirrol moduladores alostéricos negativos de nr2b
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
ECSP12012065A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
UY35469A (es) Moduladores de p2x7
UY35142A (es) Derivados de triazolopirazinas como inhibidores de brd4
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
GT201200004A (es) Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria
UY33272A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
CR20150440A (es) Nuevos derivados de piridina
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200807